Skip to main content

核医学市場は世界的なビジネス予測2030年に急成長しています

 


The global radiopharmaceuticals market is poised to grow at a significant pace, owing to growing demand for non-invasive techniques, availability of effective cancer treatment, and ability to observe the functioning of the organ from outside the body. Furthermore, increasing incidence of cancer & cardiovascular aliments, growing demand for alpha radio immunotherapy-based targeted cancer treatment, mounting call for nuclear imaging techniques, and advancements in radiotracers are expected to open new avenues in the radiopharmaceuticals market. Factors that are expected to drive the use of radiopharmaceuticals include changing lifestyle, elevated levels of stress, and ability to identify various diseases sooner than other diagnostic tests. However, factors such as supply volatility & logistical challenges, stringent regulatory vigil, and competition from conventional diagnostic procedures are anticipated to impede the market growth.

The global radiopharmaceuticals market is expected to garner $8,207.5 million by 2022.

Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/1131

The oncology segment contributed more than half of the market share in the overall radiopharmaceuticals market in 2015 and is expected to continue the same trend owing to perpetual rise in the number of cancer cases. The SPECT modality segment dominated the radiopharmaceuticals market in 2015, whereas the PET modality segment is anticipated to grow at a comparatively higher CAGR of 8.3% from 2016 to 2022. PET segment is driven by better quality of image and higher precision in diagnosis. Other reasons attributed to its sustained dominance are growing R&D activities especially in developing economies and widening scope of radiopharmaceutical applications such as thyroid, oncology, and bone pain palliation.

Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/1131

The Asia-Pacific radiopharmaceuticals market is expected to offer lucrative growth opportunities during the forecast period owing to aging population and increasing cancer incidences. The leading Asia-Pacific countries, such as China, Japan, and Australia would exhibit a steady growth rate.

The Major Key Players Are:

·        Mallinckrodt plc.

·        General Electric

·        Medtronic Inc.

·        Bayer AG

·        Cardinal Health Inc.

·        Lantheus Medical Imaging, Inc.

·        IBA Group

·        Bracco Imaging S.p.A.

·        NTP Radioisotopes SOC Ltd.

Key findings of Radiopharmaceuticals Market:

  • Therapeutics segment is projected to be the fastest growing segment in the radiopharmaceuticals market, registering a CAGR of 16.9% from 2016 to 2022.
  • SPECT modality segment is expected to dominate the radiopharmaceuticals market in 2015 and expected to retain its position throughout the study period.
  • Thyroid application segment is expected to exhibit double-digit CAGR of 11%.
  • Oncology application segment is expected to continue to lead the radiopharmaceuticals market, accounting for close to 60% share by 2022.
  • Asia-Pacific is projected to be the fastest growing radiopharmaceuticals market, registering a CAGR of 8.4%.

Access Full Report @ https://www.alliedmarketresearch.com/nuclear-medicine-radiopharmaceuticals-market

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

Labels:

Comments

Post a Comment

Popular posts from this blog

外科ナビゲーションシステム市場 Expected to Reach $963 Million by 2022

Surgical navigation systems market was valued at   $628 million   in 2015, and is projected to reach   $963 million   by 2022, growing at a CAGR of 6.3% from 2016 to 2022, according to a new report published by Allied Market Research. Optical navigation systems segment is expected to grow at the highest growth rate during the forecast period, owing to benefits such as minimum radiation exposure and preciseness & accuracy during complex surgeries. The major factors that drive the growth of this market include rise in adoption of minimal invasive surgeries, improvement in healthcare infrastructure in emerging economies, numerous technological advancements, increase in incidence of ENT and neurosurgery-related disorders, and growth in knee replacement surgeries globally. However, high cost of these systems and stringent FDA rules are the major barriers that restrain the market growth. Get access to detailed report at:   https://www.alliedmarketresearch.com/sur...
Post a Comment
Read more

抗真菌薬市場 to Reach $17.72 Billion by 2023 at 3.7% CAGR

According to the report, the global Antifungal Drugs market generated $14.23 billion in 2017 and is estimated to reach $17.72 billion by 2023, growing at a CAGR of 3.7% from 2017 to 2023. The report offers a detailed analysis of the key segments, top investment pockets, changing dynamics, market size & estimations, and competitive scenario. Favorable government funds to combat the antifungal diseases along with the increasing prevalence of fungal infection drive the growth of the market. Furthermore, rising awareness levels pertaining to myriad fungal infections supplement the market growth. However, the growing population with antifungal drug resistance and the presence of counterfeit drugs and side effects of antifungal drugs restrict the growth. On the other hand, patent expirations and increasing funding from public & private organizations offer lucrative opportunities for the market. Request Report Sample at:  https://www.alliedmarketresearch.com/request-sample/2370 B...
Post a Comment
Read more